A007575 Stock Overview

Operates as a pharmaceutical company primarily in South Korea. More details

A007575 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	2/6
Financial Health	4/6
Dividends	1/6

Rewards

Became profitable this year

Risk Analysis

Earnings have declined by 15.9% per year over past 5 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Ilyang Pharmaceutical Co.,Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ilyang PharmaceuticalLtd
Historical stock prices
Current Share Price	₩12,350.00
52 Week High	₩15,500.00
52 Week Low	₩9,470.00
Beta	0.83
1 Month Change	8.33%
3 Month Change	10.37%
1 Year Change	-17.94%
3 Year Change	-52.50%
5 Year Change	-33.96%
Change since IPO	45.29%

Recent updates

Shareholder Returns

	A007575	KR Pharmaceuticals	KR Market
7D	-0.5%	2.0%	1.7%
1Y	-17.9%	-4.5%	-6.1%

Return vs Industry: A007575 underperformed the KR Pharmaceuticals industry which returned -4.5% over the past year.

Return vs Market: A007575 underperformed the KR Market which returned -6.1% over the past year.

Price Volatility

Is A007575's price volatile compared to industry and market?
A007575 volatility
A007575 Average Weekly Movement	6.0%
Pharmaceuticals Industry Average Movement	4.8%
Market Average Movement	6.2%
10% most volatile stocks in KR Market	12.5%
10% least volatile stocks in KR Market	2.9%

Stable Share Price: A007575 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A007575's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1946	637	Dong-Yeon Kim	home.ilyang.co.kr

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages.

Ilyang Pharmaceutical Co.,Ltd Fundamentals Summary

How do Ilyang PharmaceuticalLtd's earnings and revenue compare to its market cap?
A007575 fundamental statistics
Market cap	₩232.91b
Earnings (TTM)	₩9.77b
Revenue (TTM)	₩268.86b

23.8x

P/E Ratio

0.9x

P/S Ratio

Is A007575 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A007575 income statement (TTM)
Revenue	₩268.86b
Cost of Revenue	₩157.46b
Gross Profit	₩111.40b
Other Expenses	₩101.63b
Earnings	₩9.77b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	542.26
Gross Margin	41.43%
Net Profit Margin	3.63%
Debt/Equity Ratio	44.4%

How did A007575 perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

28%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 01:11
End of Day Share Price	2025/05/16 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ilyang Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hyung Soo Kim	Cape Investment & Securities Co., Ltd.
Jae Hoon Shin	LS Securities Co., Ltd.
Jaechul Park	Mirae Asset Securities Co., Ltd. (Pre-Merger)

Ilyang PharmaceuticalLtd KOSE:A007575 Stock Report